Target intelligence / Profile preview

Cytochrome b-c1 complex subunit 2, mitochondrial (UQCRC2)

Target
UQCRC2
Molecular classification
Enzyme (component of mitochondrial electron transport chain, Complex III), Mitochondrial respiratory chain complex subunit, Peptidase M16 family (structural context)
01

Overview

Cytochrome b-c1 complex subunit 2, mitochondrial (UQCRC2), is a nuclear-encoded core protein of mitochondrial Complex III (ubiquinol-cytochrome c reductase) within the electron transport chain. It is essential for assembly and stabilization of Complex III and proper electron transfer from ubiquinol to cytochrome c, thus driving oxidative phosphorylation and ATP synthesis. UQCRC2 is upregulated or downregulated in certain cancers and its mutations lead to complex III deficiency, manifesting as mitochondrial disease with variable systemic symptoms. The protein plays roles not only in energy metabolism, but regulation of mitophagy under stress via AMPK-NFE2L2/NRF2 pathways, making it a potential biomarker and therapeutic target in specific disease contexts.

Other names
UQCRC2QCR2UQCR2Core protein IIComplex III subunit 2Ubiquinol-cytochrome-c reductase complex core protein 2MC3DN5
02

Mechanism of action

Drugs targeting the mitochondrial respiratory chain typically inhibit electron transfer, leading to reduced ATP production and oxidative stress. For experimental agents acting on complex III, the blockade impedes activity of subunits including UQCRC2, but selective molecular inhibition for UQCRC2 is not established.

03

Biological functions

Cellular respirationAssembly and stabilization of mitochondrial Complex IIIElectron transport/oxidative phosphorylationRegulation of mitophagy under cellular stress (AMPK-mediated)Potential involvement in mitochondrial protein processing
04

Disease associations

Mitochondrial complex III deficiency, nuclear type 5 (genetic mitochondrial disease)Metabolic disorders (including neonatal metabolic decompensation)Cancer (colorectal adenocarcinoma: upregulated, linked with poor prognosis; gastric cancer: downregulation associated with tumor suppression)Hepatic dysfunction, renal tubulopathy, neuromuscular disorders (linked to complex deficiencies)
05

Safety considerations

Targeting mitochondrial respiratory chain proteins like UQCRC2 carries risk of profound cellular energy failure, lactic acidosis, multi-organ dysfunction, and off-target toxicity especially in tissues with high metabolic demandSafety of direct UQCRC2 modulation not established; inhibition may lead to mitochondrial dysfunction similar to genetic deficiencies
06

Interacting drugs

No direct drugs currently approved or well-characterized as interacting with UQCRC2 in clinical use. DrugBank and HMDB list the biochemical role but not interacting agents. Mitochondrial complex III inhibitors (e.g., antimycin A, myxothiazol) theoretically target the complex as a whole, not specifically UQCRC2.
07

Biomarkers

UQCRC2 expression levels are potential biomarkers for tumor progression (colorectal cancer prognosis, gastric cancer suppression), mitochondrial disease diagnosis, and monitoring of mitophagy response in hepatic injury

Beyond the preview

Go deeper on Cytochrome b-c1 complex subunit 2, mitochondrial (UQCRC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome b-c1 complex subunit 2, mitochondrial (UQCRC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call